Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC).

臺大醫院;臺大醫院-腫瘤醫學部;臺大醫院-醫學研究部;臺大醫學院-腫瘤醫學研究所;臺大醫學院-臨床醫學研究所;Yang, James Chih-HsinJames Chih-HsinYangAhn, Myung-JuMyung-JuAhnDickgreber, Nicolas J.Nicolas J.DickgreberHalmos, BalazsBalazsHalmosHirsh, VeraVeraHirshHochmair, Maximilian J.Maximilian J.HochmairLevy, Benjamin PhilipBenjamin PhilipLevyDe Marinis, FilippoFilippoDe MarinisMok, TonyTonyMokO'Byrne, KennethKennethO'ByrneOkamoto, IsamuIsamuOkamotoSchuler, Martin H.Martin H.SchulerSebastian, MartinMartinSebastianShah, Riyaz N. H.Riyaz N. H.ShahTan, Eng-HuatEng-HuatTanYamamoto, NobuyukiNobuyukiYamamotoMarten, AngelaAngelaMartenMassey, DanDanMasseyWind, SvenSvenWindCarbone, David PaulDavid PaulCarbone2017-06-222018-07-062017-06-222018-07-062015http://ntur.lib.ntu.edu.tw//handle/246246/279903[SDGs]SDG3Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC).